TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02365792

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Clinical Decision Support Tool for Prehospital Care
Description: A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Decision Support Tool for Prehospital Care
Description: A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Decision Support Tool for Prehospital Care
Description: A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care.
Study: NCT02761278

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial biopsy
Study: NCT03103568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone in Arm A
Description: 4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: A 500 mg tablet is given as single oral dose 2 weeks apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorzoxazone
Description: A 250 mg tablet is given as single oral dose 2 weeks apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.
Study: NCT04662645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03810053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App/Online Module
Description: Short didactic explainer video that will provide information about cancers and benefits of uptake of cancer prevention and early detection measures.
Study: NCT03368079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Suction Catheter
Description: The negative pressure suction device to be used in the study will be a Foley catheter. The catheter will be placed through the gastrostomy tube site, directed retrograde through the esophagus, and terminating in the PES.
Study: NCT01329172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polyunsaturated fatty acids n-3
Description: polyunsaturated fatty acids n-3 1 gram per day during two months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sun flower oil with Poly Unsaturated Fatty Acid 1g/day
Study: NCT03103568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone in Arm B
Description: 4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.
Study: NCT00658450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation training
Description: A computerised cognitive training package where children will be required to complete several cognitive tasks. The aim is to strengthen the different cognitive processes during these tasks which in turn may lead to improve cognitive processes.~Children will complete these tasks in 16 session for 8 weeks.
Study: NCT02150291

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Study: NCT04400916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: A single drop administered topically

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Balanced Salt Solution
Description: A single drop administered topically
Study: NCT02150291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurobion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurobion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04270565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Field Gait-Training
Description: The intervention will deliver a series of vibrations on the participants' wrists through the Garmin when the sensors indicate that their contact time in milliseconds exceeds a threshold. The runners will be asked to reduce the amount of time their foot is in contact with the ground by picking their feet up more quickly. Participants will also receive a series of exercises based on noted impairments at baseline. The feedback during running will be completed twice per week for four weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: Participants will receive a series of exercises based on noted impairments at baseline. Exercises will be completed twice per week for four weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: Participants will receive a series of exercises based on noted impairments at baseline. Exercises will be completed twice per week for four weeks.
Study: NCT00119769

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 0.7 mg/day injected subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin (human recombinant Growth hormone)
Description: Genotropin, 0.7 mg/day injected subcutaneously
Study: NCT03572959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1 % topical triamcinolone acetonide
Description: 0.1 % topical triamcinolone acetonide preparation was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIROIaser
Description: Oral Lichen Planus lesions were irradiated with a 970-nm diode laser with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly (once every third day) for two months until the resolution of signs for a maximum of ten sessions.
Study: NCT01723046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with new upper limb robot assisted therapy device
Description: During 8 weeks, 3 times a week, 1 hour therapy sessions with the device
Study: NCT02810769

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry drink
Description: Cold pressed berry drink standardised to contain 500mg of berry polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Sugar matched control containing berry flavouring and no phytochemicals

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Powdered berry drink
Description: Berry drink made from a powder concentrate standardised to contain 500mg of polyphenols
Study: NCT00856596

Intervention type: DRUG
Group type: OTHER
Intervention: Sertaconazole nitrate cream 2%
Description: Once a day topical cream
Study: NCT03530254

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PGT-A
Description: PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PGT-A
Description: PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ERA Test
Description: The ERA test requires an endometrial biopsy and will determine if the endometrium is receptive or not by analysing the expression levels of 236 genes involved in endometrial receptivity, to assess the optimal time to place an embryo into the uterus and promote a successful implantation and pregnancy.
Study: NCT03982108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with knotless suture-bridge technique
Description: A posterior portal will be established to obtain adequate visualization and an anterior portal will be established through rotator interval as a working portal for diagnostic arthroscopy and debridement. Then additional portals will be established and preperation of tendon will be performed and a burr will be used for footprint preperation.~After determination of proper anchor locations, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the rotator cuff and will be used to create a suture bridge over the tendon. Then these limbs will be loaded to anchors which will form the lateral row without tying the suture limbs at the medial row. These lateral anchors will be inserted to adequate location, just lateral and distal to greater tuberosity with adequate suture-bridge tension over the rotator cuff.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff repair with knot-tying suture-bridge technique
Description: After the same preparation procedure as in knotless suture-bridge technique, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the tendon and tied in a horizontal mattress suture pattern. After the establishment of medial row, suture limbs will be used to form a suture bridge over the tendon and will be loaded to lateral row anchors which then will be inserted lateral to greater tuberosity in a similar way to knotless repair technique.
Study: NCT04136093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the MED
Description: The MED diet will be composed of the basis food items traditional for the Mediterranean region i.e. olive oil, nuts, vegetables, fruits, and fish and this diet will be given an ad libitum approach. The MED diet will be giving a higher proportion of fat, at least 40% of the total energy, with 20% of the total energy from MUFAs, and less proportion of carbohydrates. To ensure the assumed supply of MUFAs and polyunsaturated fatty acids (PUFAs), the participants will be asked to daily intake 60 g (6 spoons) of extra virgin olive oil and 30 g (6 pieces) walnuts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the DASH
Description: The DASH diet will be giving a higher proportion of carbohydrates, at least 60% of total energy and less fat. The DASH diet will be composed wholegrain cereal products, fruit, vegetables, low-fat dairy products, fish, seafood, poultry, beans, seeds and nuts and will be recommending eating of the traditional polish food items for example oatmeal, rye bread, barley groats, apples, plums, etc. and reducing the supply of salt, sweets, sugars, fats especially saturated fats and red meat. In our study, the DASH diet will be given an ad libitum approach. The sufficient supply of carbohydrates and β glucans in the DASH diet will be ensured by daily consumption at least 50g oatmeal and 50g of barley groats.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control diet
Description: The control group will only receive oral dietary recommendations based on the Harvard model Healthy Eating Plate, that recommend to eat a half of plate of vegetables and fruit, a quarter of plate of whole grains products, and a quarter of plate of protein products for one meal.
Study: NCT01262560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manuka honey in liquid form
Description: Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manuka honey in lozenge form
Description: Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive care
Description: Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~1. A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~2. Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed.
Study: NCT03026231

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRIM-DJ2727
Description: Thirty eligible subjects with PD will be randomly assigned to receive either PRIM-DJ2727 in orally administered enteric-coated capsules or placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for PRIM-DJ2727)
Description: Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
Study: NCT04772625

Intervention type: DEVICE
Intervention: Patellofemoral arthroplasty
Description: Insertion of an artificial joint between the front of the femur and the back of the patella. The femoral component consists of a metal implant, and the patellar component is a polyethylene implant. The two components replace the original articular cartilage of the patellofemoral joint.
Study: NCT04587830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20
Description: Investigational Medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Radiotherapy and TMZ are standard front-line therapy for newly diagnosed GBM.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Radiotherapy and TMZ are standard front-line therapy for newly diagnosed GBM.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Investigational Medicine
Study: NCT02543073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Description: MSCs will be given at a median dose of 1×10\^6 cells/kg once weekly for 4 weeks as one cycle treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZM
Description: AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM
Description: AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid
Description: Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
Study: NCT02905539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Study: NCT03292640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-03 (0.1% tazarotene) Lotion
Description: DFD-03 Lotion (0.1% tazarotene) - twice daily application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DFD-03 (0% tazarotene) Lotion (Placebo)
Description: DFD-03 Vehicle Lotion (0% tazarotene) - twice daily application
Study: NCT02122666

Intervention type: PROCEDURE
Intervention: muscle biopsy
Description: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).

Intervention type: PROCEDURE
Intervention: muscle biopsy
Description: A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
Study: NCT03781973

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Data platform +Quality Performance feedback reports
Description: Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Data platform +Quality Performance feedback reports
Description: Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.
Study: NCT03685903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CapsoCam® Plus (SV-3) capsule endoscope
Description: Endoscope Capsule
Study: NCT02337101

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EUC + Early intervention programme
Description: All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion.
Study: NCT04055272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile text messaging intervention
Description: Participants in the intervention arm will receive text messages to their mobile phones designed to communicate the risks of indoor tanning and motivate cessation. The intervention exposure lasts for 4 weeks with messages sent 2 days each week. It is an interactive intervention that engages participants by asking them to respond to prompts, and sending indoor tanning message content in return on message days.
Study: NCT03442556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib Camsylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Given PO
Study: NCT01788397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
Study: NCT02620800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 5 fluorouracil (5-FU) (180 mg/m\^2/day for 14 days) by CIVI via ambulatory pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel (75 mg/m\^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium leucovorin
Description: calcium leucovorin (20 mg/m\^2) IV bolus, on Days 1, 8, 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin (40 mg/m\^2) as a 60-min IV infusion on Days 1, 8, and 15
Study: NCT04475419

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
Description: covering the affected molar with preformed metal crown cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preformed stainless steel crowns cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
Description: covering the affected molar with preformed metal crown cemented by glass ionomer luting cement(Ketac Cem, 3M Espe)
Study: NCT01774669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YouGrabber training device from YouRehab Ltd.
Description: Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapy (PT, OT)
Description: Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
Study: NCT03545087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanabecestat
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.
Study: NCT03435120

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03312790

Intervention type: DEVICE
Group type: OTHER
Intervention: Tasks
Description: Augmented reality device Real condition

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tasks
Description: Augmented reality device Real condition